Denali Therapeutics Inc. (DNLI): Price and Financial Metrics
GET POWR RATINGS... FREE!
DNLI POWR Grades
- DNLI scores best on the Sentiment dimension, with a Sentiment rank ahead of 63.52% of US stocks.
- DNLI's strongest trending metric is Momentum; it's been moving up over the last 179 days.
- DNLI ranks lowest in Stability; there it ranks in the 19th percentile.
DNLI Stock Summary
- DNLI's price/sales ratio is 35.37; that's higher than the P/S ratio of 95.71% of US stocks.
- In terms of twelve month growth in earnings before interest and taxes, DENALI THERAPEUTICS INC is reporting a growth rate of -1,097.51%; that's higher than only 1.46% of US stocks.
- Revenue growth over the past 12 months for DENALI THERAPEUTICS INC comes in at -68.64%, a number that bests just 2.5% of the US stocks we're tracking.
- Stocks that are quantitatively similar to DNLI, based on their financial statements, market capitalization, and price volatility, are FATE, MRTX, MORF, ANAB, and TSP.
- DNLI's SEC filings can be seen here. And to visit DENALI THERAPEUTICS INC's official web site, go to www.denalitherapeutics.com.
DNLI Valuation Summary
- DNLI's price/sales ratio is 36.8; this is 1740% higher than that of the median Healthcare stock.
- DNLI's price/sales ratio has moved NA NA over the prior 60 months.
Below are key valuation metrics over time for DNLI.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| DNLI | 2022-11-25 | 36.8 | 5.0 | -13.5 | -13.2 |
| DNLI | 2022-11-23 | 37.3 | 5.1 | -13.7 | -13.4 |
| DNLI | 2022-11-22 | 37.2 | 5.1 | -13.6 | -13.4 |
| DNLI | 2022-11-21 | 36.0 | 4.9 | -13.2 | -13.0 |
| DNLI | 2022-11-18 | 36.8 | 5.0 | -13.5 | -13.3 |
| DNLI | 2022-11-17 | 35.5 | 4.8 | -13.0 | -12.8 |
DNLI's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- DNLI has a Quality Grade of C, ranking ahead of 72.1% of graded US stocks.
- DNLI's asset turnover comes in at 0.231 -- ranking 185th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows DNLI's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.231 | 1 | 0.028 |
| 2021-06-30 | 0.249 | 1 | 0.058 |
| 2021-03-31 | 0.279 | 1 | 0.069 |
| 2020-12-31 | 0.334 | 1 | 0.102 |
| 2020-09-30 | 0.032 | 1 | -0.411 |
| 2020-06-30 | 0.044 | 1 | -0.416 |
DNLI Price Target
For more insight on analysts targets of DNLI, see our DNLI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $85.55 | Average Broker Recommendation | 1.5 (Moderate Buy) |
DNLI Stock Price Chart Interactive Chart >
DNLI Price/Volume Stats
| Current price | $31.35 | 52-week high | $48.46 |
| Prev. close | $30.18 | 52-week low | $20.24 |
| Day low | $29.76 | Volume | 277,130 |
| Day high | $31.41 | Avg. volume | 661,722 |
| 50-day MA | $29.79 | Dividend yield | N/A |
| 200-day MA | $30.02 | Market Cap | 4.26B |
Denali Therapeutics Inc. (DNLI) Company Bio
Denali Therapeutics Inc. engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company’s lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson’s disease. It is also developing therapeutics for the treatment of Parkinson’s, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was founded in 2013 and is based in South San Francisco, California.
Latest DNLI News From Around the Web
Below are the latest news stories about DENALI THERAPEUTICS INC that investors may wish to consider to help them evaluate DNLI as an investment opportunity.
Denali Therapeutics Inc. (DNLI) did well last session?As of Tuesday, Denali Therapeutics Inc.’s (NASDAQ:DNLI) stock closed at $31.21, up from $31.00 the previous day. While Denali Therapeutics Inc. has overperformed by 0.68%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, DNLI fell by -37.73%, with highs and lows ranging from $51.39 to $20.24, […] |
Denali Therapeutics Third Quarter 2022 Earnings: Misses ExpectationsDenali Therapeutics ( NASDAQ:DNLI ) Third Quarter 2022 Results Key Financial Results Revenue: US$3.56m (down 33% from... |
Morgan Stanley Keeps Their Buy Rating on Denali Therapeutics (DNLI)In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Denali Therapeutics (DNLI - Research Report), with a price target of $60.00. The company's shares opened today at $27.91.According to TipRanks, Harrison is a 5-star analyst with an average return of 6.5% and a 51.12% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Galapagos, Biogen, and BioMarin Pharmaceutical.Denali Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $57.17, a 104.84% upside from current levels. In a report released today, Berenberg Bank also maintained a Buy rating on the stock with a $50.00 price target. |
Why Have Denali Therapeutics Inc. (NASDAQ: DNLI) Shares Declined So Much?Denali Therapeutics Inc. (NASDAQ:DNLI) price closed lower on Friday, November 04, dropping -7.54% below its previous close. A look at the daily price movement shows that the last close reads $30.63, with intraday deals fluctuated between $26.52 and $30.62. The company’s 5Y monthly beta was ticking 1.66. Taking into account the 52-week price action we … Why Have Denali Therapeutics Inc. (NASDAQ: DNLI) Shares Declined So Much? Read More » |
Denali (DNLI) Lags Q3 Earnings Estimates, Pipeline in FocusDenali (DNLI) posts a wider Q3 loss. Collaboration revenues decline year over year. |
DNLI Price Returns
| 1-mo | 9.31% |
| 3-mo | 12.04% |
| 6-mo | 28.22% |
| 1-year | -32.23% |
| 3-year | 76.22% |
| 5-year | N/A |
| YTD | -29.71% |
| 2021 | -46.75% |
| 2020 | 380.83% |
| 2019 | -15.68% |
| 2018 | 32.10% |
| 2017 | N/A |
Continue Researching DNLI
Here are a few links from around the web to help you further your research on Denali Therapeutics Inc's stock as an investment opportunity:Denali Therapeutics Inc (DNLI) Stock Price | Nasdaq
Denali Therapeutics Inc (DNLI) Stock Quote, History and News - Yahoo Finance
Denali Therapeutics Inc (DNLI) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...